Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $44,300 | 16 | 98.0% |
| Grant | $472.90 | 1 | 1.0% |
| Food and Beverage | $356.05 | 7 | 0.8% |
| Travel and Lodging | $60.88 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca AB | $43,223 | 16 | $0 (2021) |
| Kyowa Kirin Co., Ltd | $1,138 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $575.30 | 3 | $0 (2018) |
| Otsuka Pharmaceutical Co., Ltd. | $110.65 | 1 | $0 (2023) |
| Aesculap, Inc. | $59.49 | 1 | $0 (2018) |
| AstraZeneca UK Limited | $55.30 | 2 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $28.21 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $110.65 | 1 | Otsuka Pharmaceutical Co., Ltd. ($110.65) |
| 2021 | $6,188 | 3 | AstraZeneca AB ($6,188) |
| 2020 | $10,813 | 5 | AstraZeneca AB ($9,675) |
| 2019 | $10,293 | 6 | AstraZeneca AB ($10,238) |
| 2018 | $14,084 | 8 | AstraZeneca AB ($13,523) |
| 2017 | $3,702 | 3 | AstraZeneca AB ($3,600) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/15/2023 | Otsuka Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $110.65 | General |
| 11/02/2021 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $2,137.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/09/2021 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/07/2021 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/03/2020 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/09/2020 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/19/2020 | Kyowa Kirin Co., Ltd | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 02/25/2020 | Kyowa Kirin Co., Ltd | — | Travel and Lodging | In-kind items and services | $37.88 | General |
| 02/14/2020 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/17/2019 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/03/2019 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/05/2019 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $4,162.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/29/2019 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $27.65 | General |
| 03/29/2019 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $27.65 | General |
| 03/06/2019 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/11/2018 | Aesculap, Inc. | CAIMAN VESSEL SEALERS (Device) | Food and Beverage | Cash or cash equivalent | $59.49 | General |
| Category: LAPAROSCOPY | ||||||
| 11/26/2018 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $4,275.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/08/2018 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $3,825.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/27/2018 | Janssen Scientific Affairs, LLC | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $28.21 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/16/2018 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $472.90 | General |
| 02/09/2018 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/02/2018 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/02/2018 | AstraZeneca AB | FARXIGA (Drug) | Travel and Lodging | Cash or cash equivalent | $23.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/24/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/11/2017 | AstraZeneca AB | FARXIGA (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 4 | 71 | 129 | $38,571 | $9,241 |
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 56 | $16,520 | $4,824 | 29.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 31 | 49 | $16,156 | $2,551 | 15.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 11 | 11 | $4,257 | $1,037 | 24.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 13 | 13 | $1,638 | $829.95 | 50.7% |
About Dr. Andrew Levey, M.D
Dr. Andrew Levey, M.D is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902830664.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Levey, M.D has received a total of $45,190 in payments from pharmaceutical and medical device companies, with $110.65 received in 2023. These payments were reported across 26 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($44,300).
As a Medicare-enrolled provider, Levey has provided services to 71 Medicare beneficiaries, totaling 129 services with total Medicare billing of $9,241. Data is available for 1 year (2020–2020), covering 4 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Boston, MA
- Active Since 07/10/2006
- Last Updated 08/09/2010
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1902830664
Products in Payments
- FARXIGA (Drug) $43,325
- CAIMAN VESSEL SEALERS (Device) $59.49
- INVOKANA (Drug) $28.21
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Boston
David Friedman, M.d, M.D
Nephrology — Payments: $20.3M
Martin Pollak, Md, MD
Nephrology — Payments: $20.3M
Dr. Dennis Ausiello, Md, MD
Nephrology — Payments: $4.4M
Dr. Ajay Singh, Md, MD
Nephrology — Payments: $1.2M
Dr. Leslie Fang, Md, MD
Nephrology — Payments: $795,357
Dr. Jean Francis, M.d, M.D
Nephrology — Payments: $217,413